Paris Diderot University

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Retrieved on: 
onsdag, februari 28, 2024
ASRS, Senior, Paris Diderot University, SAB, Reno 1868 FC, Growth, Visual acuity, University, DED, Telecanthus, Organization, Principal, Teaching hospital, Retina, Anthropology, Diabetic retinopathy, Therapy, OCS, Inflammation, CSO, DME, American Academy, Simmons University, M.A, Clinical research, ASCRS, Society, Cerebral edema, Eastern Virginia Medical School, Patient, Partner (business rank), Medicine, Pharmaceutical industry

In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.

Key Points: 
  • In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.
  • “2024 promises to be another exciting year for Oculis as we advance our late-stage clinical development programs.
  • I am certain that the extensive experience each of them brings will be invaluable to Oculis,” said Riad Sherif, M.D., Chief Executive Officer of Oculis.
  • Oculis also announced today key executive appointments to bolster its leadership and scientific advisory teams.

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Retrieved on: 
onsdag, februari 21, 2024
Cancer, AstraZeneca, EVP, Drug development, Bristol Myers Squibb, RAS, University, RAF, Therapy, Patient, Oncology, Novartis, Paris Diderot University, Physician, Nursing

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.

Key Points: 
  • Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
    Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595
    BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
  • Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company’s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions.
  • Dr. Germa added, “I am thrilled to be joining Ikena at a time when it is primed for clinical inflection across the pipeline.
  • Dr. Santillana’s leadership was integral to bringing our programs into the clinic, and we wish him well in his future endeavors.”

Versameb Strengthens its Board of Directors

Retrieved on: 
tisdag, juli 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.

Versameb Strengthens its Board of Directors

Retrieved on: 
tisdag, juli 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

Retrieved on: 
torsdag, april 13, 2023
San Francisco, KOL, University, EPP, University of California, San Francisco, AURORA, Research, IRON, Patient, Erythropoietic protoporphyria, Porphyria, Paris Diderot University, Epidemiology, Pharmaceutical industry, Gastroenterology

The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.

Key Points: 
  • The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.
  • Intended for investors and other interested audiences, the virtual event will feature presentations from leading porphyria experts, who will provide a disease overview and discuss epidemiology, pathophysiology, disease burden, and unmet need associated with EPP.
  • A live webcast of the event will be available in the Events and Presentations section of the Investor page of Disc’s website (https://ir.discmedicine.com/).
  • Please register for the event on the Events and Presentations page of Disc’s website or by clicking this link .

DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board

Retrieved on: 
tisdag, mars 14, 2023
Oncology, Health, Other Health, Clinical Trials, Research, Science, Biotechnology, Macrophage, Inflammation, University, Algiers, IUIS, International Union of Immunological Societies, University of Paris, Mount Sinai School, Disease, Homeostasis, Icahn School of Medicine at Mount Sinai, Paris Diderot University, Multimedia, National academy, Mount Sinai, Coronavirus Scientific Advisory Board, DEM, Cancer, B cell, Stanford University, Vaccine, Medicine

DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and macrophages to eliminate cancer, today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.

Key Points: 
  • DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and macrophages to eliminate cancer, today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.
  • Dr. Merad is credited with identifying the tissue resident macrophage lineage and revealing its distinct role in organ physiology and pathophysiology.
  • Dr. Merad is the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.
  • She holds a Master’s degree in biotechnology and a Ph.D. in immunology from Stanford University and University Paris VII.

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

Retrieved on: 
torsdag, december 15, 2022
Roche, Paris Diderot University, Micrometer, Arenavirus, Head, Tango, Merck, Global health, Prostate Cancer Foundation, School, CD8, Cancer, Merck & Co., Human papillomavirus infection, HBV, Doctor of Philosophy, Neck, Vaccine, Infection, Internal medicine, Gilead, HIV, Research, Senior, MorphoSys, Development, Patient, Therapy, KRAS, Pharmaceutical industry, Novartis

“Katia has had a major impact on HOOKIPA’s clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021.

Key Points: 
  • “Katia has had a major impact on HOOKIPA’s clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021.
  • “We are also excited to welcome Malte to our Board.
  • She has served as the Company’s Executive Vice President, Clinical Research and Development since July 2022.
  • Dr. Peters serves as Chief Research and Development Officer at MorphoSys and will retire from the company at the end of 2022.

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board

Retrieved on: 
måndag, november 28, 2022
Doctor of Philosophy, CDTI, Executive, University, MicroRNA, Corporation, Myotonic dystrophy, Knowledge, Biotechnology, Patient, Business development, Centre for the Development of Industrial Technology, Eppendorf (company), The Advisory Board Company, Molecular biology, NEOMA Business School, Development, Industrial technology, Valneva SE, Paris Diderot University, Pharmaceutical industry, Management

Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.

Key Points: 
  • Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.
  • Beatriz Llamus, CEO of Arthex Biotech, commented: "We are very pleased to have Frdricjoin us as Arthex Biotech's Executive Chairman of the Board.
  • Dr. Legros, the new Executive Chairman of the Board of Directors, said, "Arthex Biotech is a very promising company with an exciting lead program targeting diseases with high unmet medical needs in which microRNAs play a role.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board

Retrieved on: 
måndag, november 28, 2022
Doctor of Philosophy, CDTI, Executive, University, MicroRNA, Corporation, Myotonic dystrophy, Knowledge, Biotechnology, Patient, Business development, Centre for the Development of Industrial Technology, Eppendorf (company), The Advisory Board Company, Molecular biology, NEOMA Business School, Development, Industrial technology, Valneva SE, Paris Diderot University, Pharmaceutical industry, Management

Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.

Key Points: 
  • Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.
  • Beatriz Llamus, CEO of Arthex Biotech, commented: "We are very pleased to have Frdricjoin us as Arthex Biotech's Executive Chairman of the Board.
  • Dr. Legros, the new Executive Chairman of the Board of Directors, said, "Arthex Biotech is a very promising company with an exciting lead program targeting diseases with high unmet medical needs in which microRNAs play a role.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH

Retrieved on: 
onsdag, september 7, 2022
Beaujon Hospital, Partnership, Vascular disease, Paris Diderot University, CEO, National Institute, Imaging, SIB, Artificial intelligence, Liver, INSERM, Trial of the century, CEA, Seminal vesicles, Pathology, Artificiality, Digital pathology, Commissariat, Physics, Swiss Institute of Bioinformatics, Fatty liver disease, Diagnosis, Diabetes, Medical research, Inflammation, Type 2 diabetes, Fibrosis, GLOBE, Biostatistics, Leadership, Princeton University, NASH, University, Assistance, Data, Patient, QUID, Medical imaging, T2D, Beaujon

The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.

Key Points: 
  • The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
  • This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D patients.
  • Its multivendor platform, FibroNest, is delivered worldwide via the cloud and used in multiple pre-clinical and clinical studies across several fibrotic conditions.
  • For more information about FibroNest and PharmaNest, visit www.pharmanest.com and www.fibronest.com